secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2026-06-17T20:05:28+00:00
Accession:  0001034842-26-000043
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel closes VEPPANU license with Arvinas/Pfizer; pays $70M upfront
-------------------------------------------------------------------

- Rigel gains exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant).
- One-time upfront payment of $70 million made to Arvinas Inc., Arvinas Operations, Arvinas Estrogen Receptor, and Pfizer.
- License agreement previously disclosed on May 12, 2026; HSR waiting period terminated early.
- No additional upfront or milestone payment details provided beyond the $70 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000043/0001034842-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000043/rigl-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001034842-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer